The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options for patients with myeloma. Recently, B-cell maturation antigen (BCMA) has emerged as a promising target for myeloma treatment due to its selective expression in malignant plasma cells. Current work in this area focuses on determining the optimal combination of therapies, treatment strategies to overcome relapse, and clinical trials to aid the development of novel BCMA-targeted treatment modalities.
VJHemOnc is joined by Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, and Karthik Ramasamy, MD, MBBS, MRCP, FRCPath, PhD, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, to discuss the latest research in myeloma presented at the American Society of Hematology (ASH) 2020 virtual annual meeting. These leading experts share their insights into emerging data on newly diagnosed myeloma, combination therapies in the relapsed setting, and novel BCMA-targeted myeloma therapies currently undergoing clinical trials such as CAR-T, BiTEs, and antibody-drug conjugates.
The post The Myeloma Sessions: Post-ASH 2020 UK Discussion appeared first on VJHemOnc.
